NUTRITION 21 Bioaktie?
| eröffnet am: | 28.09.04 12:03 von: | soros |
| neuester Beitrag: | 16.08.10 13:22 von: | stumpf_pft |
| Anzahl Beiträge: | 459 | |
| Leser gesamt: | 70889 | |
| davon Heute: | 20 | |
bewertet mit 3 Sternen |
||
|
|
||
433 Postings ausgeblendet.
10.08.06 15:08
#435
3181olly
@Elron
Bin Deinem Rat gefolgt und mir auch ein paar Nutri ins Depot gelegt. Mal sehen was die nähere Zukunft bringt.
Scheint ja ein ganz solider Wert zu sein.
An einem solchen Tag wie dem heutige ist es schon erstaunlich, ein sattes Plus von 9% zu sehen.
Überigens, wenn Du schon hier fragst, bei Sunwin brauchst Du meiner Meinung nach nicht nervös werden. Im Gegenteil,
Du solltest vieleicht, wenn Du noch Reserven hast, nachkaufen. So habe ich das gemacht. Aber wie gesagt, alles nur meine Meinung:
Scheint ja ein ganz solider Wert zu sein.
An einem solchen Tag wie dem heutige ist es schon erstaunlich, ein sattes Plus von 9% zu sehen.
Überigens, wenn Du schon hier fragst, bei Sunwin brauchst Du meiner Meinung nach nicht nervös werden. Im Gegenteil,
Du solltest vieleicht, wenn Du noch Reserven hast, nachkaufen. So habe ich das gemacht. Aber wie gesagt, alles nur meine Meinung:
15.08.06 17:11
#437
Elron
Achtung! Nutri rennt wech!
Eigentlich sollte man nochmal ein Thread, bezüglich Nutrition21, aufmachen!
Das Teil läuft & läuft & läuft! Schööön!!!!!
Kann nur jedem raten Nutrition21 bei Kursrücksetzer zu kaufen! oder nach-
zukaufen! Ich tue dies!!!! Denke das es z.Zt. kaum einen Wert gibt der so
kontinuierlich nach oben läuft wie Nutrition21! und das sogar bei negativen
Börsen verlauf!!! Nehmt es mir nicht krumm das ich hier soooo ne Werbung
für diese Aktie mache. Aber ich bleibe dabei! Ein ganz ganz starker Wert!!!!!!
Deswegen wünsch ich allen investierten,und oder bald investierten, viel
viel $$$$$$$$$$ !!!!!!!
ELRON :o))
Das Teil läuft & läuft & läuft! Schööön!!!!!
Kann nur jedem raten Nutrition21 bei Kursrücksetzer zu kaufen! oder nach-
zukaufen! Ich tue dies!!!! Denke das es z.Zt. kaum einen Wert gibt der so
kontinuierlich nach oben läuft wie Nutrition21! und das sogar bei negativen
Börsen verlauf!!! Nehmt es mir nicht krumm das ich hier soooo ne Werbung
für diese Aktie mache. Aber ich bleibe dabei! Ein ganz ganz starker Wert!!!!!!
Deswegen wünsch ich allen investierten,und oder bald investierten, viel
viel $$$$$$$$$$ !!!!!!!
ELRON :o))
30.08.06 23:52
#439
hoelli7
bald gehts los
http://shop.vitaminwelten.de/...icolinate-250-mcg-100-Kapseln-DL.html
also wer das Chromax noch nicht selber zu sich nimmt hier ein Link zum bestellen
kann ich jeden nur empfehlen . vor alem unbedingt noch Aktien kaufen oder nachkaufen
der Weg nach Norden ist frei. kann jeden Tag die Post abgehen mal schauen wie hoch
wir zu Weihnachhten stehen ( 3 $ )
http://shop.vitaminwelten.de/...icolinate-250-mcg-100-Kapseln-DL.html
also wer das Chromax noch nicht selber zu sich nimmt hier ein Link zum bestellen
kann ich jeden nur empfehlen . vor alem unbedingt noch Aktien kaufen oder nachkaufen
der Weg nach Norden ist frei. kann jeden Tag die Post abgehen mal schauen wie hoch
wir zu Weihnachhten stehen ( 3 $ )
23.01.07 10:14
#449
Keule
News
Super News!!!!
Sehen wir hier bald schon die 3 Euro
Nutrition 21's Selenomax(R) Suppresses Progression of the Human Immunodeficiency Virus (HIV-1) According to Study Results Published in Archives of Internal Medicine
Monday January 22, 4:00 pm ET
-- Selenomax Currently Available at CVS/pharmacy --
PURCHASE, N.Y.--(BUSINESS WIRE)--Nutrition 21, Inc. (NASDAQ: NXXI - News) announced today that daily supplementation with Selenomax®, the company's high selenium yeast product, suppressed progression of the human immunodeficiency virus (HIV-1) and improved immune cell CD4 counts in HIV-1 seropositive men and women. The benefits reported in the five-year, double-blind, placebo-controlled study conducted by researchers at the University of Miami and published in the January 22 issue of the American Medical Association's Archives of Internal Medicine, were seen in both people with HIV/AIDS on anti-retroviral therapy (ARV), and those who were not.(1)
ADVERTISEMENT
These findings are significant because boosting the immune system's CD4 cell count and suppressing viral loads (co-measurements of HIV progression and the goals of HIV treatment), can decrease the likelihood of developing complication of HIV disease and prolong life.(2)
Selenomax will be available first at CVS/pharmacy in all its 6,200 retail stores across the country, including PharmaCare Specialty Pharmacy locations, and on www.cvs.com ($15.99 for a two-month supply). Nutrition 21 will also be collaborating with additional retailers over the next several months to make Selenomax, the same nutritional supplement used in the study, even more widely available. Other forms of selenium currently available may not produce the same effects.
"This study builds on previous research showing selenium's potential role as an antioxidant in immune health and the possible consequences of selenium deficiency in people living with HIV/AIDS," said Barry Hurwitz, PhD, Professor of Psychology and Medicine at the University of Miami and lead investigator of the study. "The results support the use of high selenium yeast as an inexpensive, safe nutritional therapy in HIV spectrum disease."
Nutrition 21 established the quality standards for high selenium yeast supplements through the study of Selenomax in clinical trials. Selenomax was previously investigated by clinical researchers in a nation-wide cancer prevention study which showed beneficial effects on reducing risk of prostate cancer as reported in the Journal of the American Medical Association in 1996.(3)
"Given the significant clinical findings seen with our Selenomax brand, the immediate focus is to collaborate with retailers to ensure that the product is readily available," said Paul Intlekofer, President and CEO of Nutrition 21. "Selenomax was chosen by study investigators specifically for its absorbability, its bioavailability and because it is organic - it is the closest form of selenium to that found in nature. Other forms of commercially available selenium do not share these characteristics."
Study Findings
The double-blind, randomized, placebo-controlled trial evaluated the effects of once-daily supplementation with Selenomax high selenium yeast (200 mcg selenium) in 262 study participants seropositive for HIV-1. One hundred seventy four subjects completed nine months of treatment (91 subjects were given the supplement and 83 were given a placebo). Serum selenium levels significantly increased (> 3 SD) in more than half of the selenium treated subjects (50). In these subjects, HIV-1viral load was significantly lower (p < 0.02) and the CD4 cell count was significantly higher (p < 0.02) compared to the placebo group. The beneficial effects of Selenomax supplementation were consistent across the diverse study population regardless of age, sex, ethnicity, and past and/or current drug use. Additionally, the findings remained significant after correcting for the effects of disease-related factors, including ART regimen and adherence, HIV disease stage and duration and HCV co-infection. No adverse events were reported. The study was funded through a grant from the National Institutes of Health. The selenium used in the study was provided by Nutrition 21, Inc.
Impact of HIV & AIDS
In 2006, more than 1 million people were living with HIV/AIDS in the United States alone, and an estimated 40,000 new HIV infections are expected to occur this year.(4) While significant progress has been made in treating the virus, HIV and AIDS have claimed the lives of more than 22 million people worldwide, including more than 500,000 people in the United States.(5)
About Selenomax
Selenomax is a powerful trace mineral antioxidant. It stimulates and protects the immune system by supporting antibody production and preventing free-radical damage. Selenomax is highly absorbed and bioavailable. It contains L-selenomethionine, the natural form of selenium used by the body, which is virtually 100% absorbed and well retained. The yeast-bound L-selenomethionine which is organic, has been certified for maximum purity. More information is available at http://www.selenomax.com.
About Nutrition 21
Nutrition 21 is a nutritional bioscience company and the maker of chromium-based and omega-3 fish oil-based supplements with health benefits substantiated by clinical research. The company markets Chromax® chromium picolinate, http://www.chromax.com/, which is the most-studied form of the essential mineral chromium. Chromax, a supplement for healthy and pre-diabetic people that promotes insulin health and helps improve blood sugar metabolism, cardiovascular disease, control carbohydrate cravings and fight weight gain, is now available through food, drug and mass retailers nationwide. Nutrition 21 also developed and markets Diachrome®, http://www.diachrome.com/ , a proprietary, non-prescription, insulin sensitizer for people with type 2 diabetes. It is available in select drug retailers nationwide. Nutrition 21 holds 33 patents for nutrition products and uses, 23 of which are for chromium compounds and their uses. The Company is the exclusive importer of Icelandic fish oils, including omega-3 fatty acids, which are manufactured to pharmaceutical standards and sold under the Iceland Health® brand, http://www.icelandhealth.info. More information is available at http://www.nutrition21.com.
(1) Hurwitz, B. Suppression of Human Immunodeficiency Virus Type 1 Viral Load with Selenium Supplementation. Archives of Internal Medicine. Volume 167: January, 22 2007 (http://archinte.ama-assn.org).
(2) The Henry J. Kaiser Family Foundation. National Aids Treatment Information Project, 1998. http://www.kff.org/hivaids/1184-viral_load.cfm
(3) Clark, L.C. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. Journal of the American Medical Association. Volume 276: December 1996.
(4) Centers for Disease Control & Prevention (CDC). The Toll of the HIV Epidemic. Last reviewed April 19, 2006. http://www.cdc.gov/hiv/resources/reports/comp_hiv_prev/ epidemic_toll.htm (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
(5) UNAIDS, 2006 AIDS Epidemic Update, December 2006.
Sehen wir hier bald schon die 3 Euro
Nutrition 21's Selenomax(R) Suppresses Progression of the Human Immunodeficiency Virus (HIV-1) According to Study Results Published in Archives of Internal Medicine
Monday January 22, 4:00 pm ET
-- Selenomax Currently Available at CVS/pharmacy --
PURCHASE, N.Y.--(BUSINESS WIRE)--Nutrition 21, Inc. (NASDAQ: NXXI - News) announced today that daily supplementation with Selenomax®, the company's high selenium yeast product, suppressed progression of the human immunodeficiency virus (HIV-1) and improved immune cell CD4 counts in HIV-1 seropositive men and women. The benefits reported in the five-year, double-blind, placebo-controlled study conducted by researchers at the University of Miami and published in the January 22 issue of the American Medical Association's Archives of Internal Medicine, were seen in both people with HIV/AIDS on anti-retroviral therapy (ARV), and those who were not.(1)
ADVERTISEMENT
These findings are significant because boosting the immune system's CD4 cell count and suppressing viral loads (co-measurements of HIV progression and the goals of HIV treatment), can decrease the likelihood of developing complication of HIV disease and prolong life.(2)
Selenomax will be available first at CVS/pharmacy in all its 6,200 retail stores across the country, including PharmaCare Specialty Pharmacy locations, and on www.cvs.com ($15.99 for a two-month supply). Nutrition 21 will also be collaborating with additional retailers over the next several months to make Selenomax, the same nutritional supplement used in the study, even more widely available. Other forms of selenium currently available may not produce the same effects.
"This study builds on previous research showing selenium's potential role as an antioxidant in immune health and the possible consequences of selenium deficiency in people living with HIV/AIDS," said Barry Hurwitz, PhD, Professor of Psychology and Medicine at the University of Miami and lead investigator of the study. "The results support the use of high selenium yeast as an inexpensive, safe nutritional therapy in HIV spectrum disease."
Nutrition 21 established the quality standards for high selenium yeast supplements through the study of Selenomax in clinical trials. Selenomax was previously investigated by clinical researchers in a nation-wide cancer prevention study which showed beneficial effects on reducing risk of prostate cancer as reported in the Journal of the American Medical Association in 1996.(3)
"Given the significant clinical findings seen with our Selenomax brand, the immediate focus is to collaborate with retailers to ensure that the product is readily available," said Paul Intlekofer, President and CEO of Nutrition 21. "Selenomax was chosen by study investigators specifically for its absorbability, its bioavailability and because it is organic - it is the closest form of selenium to that found in nature. Other forms of commercially available selenium do not share these characteristics."
Study Findings
The double-blind, randomized, placebo-controlled trial evaluated the effects of once-daily supplementation with Selenomax high selenium yeast (200 mcg selenium) in 262 study participants seropositive for HIV-1. One hundred seventy four subjects completed nine months of treatment (91 subjects were given the supplement and 83 were given a placebo). Serum selenium levels significantly increased (> 3 SD) in more than half of the selenium treated subjects (50). In these subjects, HIV-1viral load was significantly lower (p < 0.02) and the CD4 cell count was significantly higher (p < 0.02) compared to the placebo group. The beneficial effects of Selenomax supplementation were consistent across the diverse study population regardless of age, sex, ethnicity, and past and/or current drug use. Additionally, the findings remained significant after correcting for the effects of disease-related factors, including ART regimen and adherence, HIV disease stage and duration and HCV co-infection. No adverse events were reported. The study was funded through a grant from the National Institutes of Health. The selenium used in the study was provided by Nutrition 21, Inc.
Impact of HIV & AIDS
In 2006, more than 1 million people were living with HIV/AIDS in the United States alone, and an estimated 40,000 new HIV infections are expected to occur this year.(4) While significant progress has been made in treating the virus, HIV and AIDS have claimed the lives of more than 22 million people worldwide, including more than 500,000 people in the United States.(5)
About Selenomax
Selenomax is a powerful trace mineral antioxidant. It stimulates and protects the immune system by supporting antibody production and preventing free-radical damage. Selenomax is highly absorbed and bioavailable. It contains L-selenomethionine, the natural form of selenium used by the body, which is virtually 100% absorbed and well retained. The yeast-bound L-selenomethionine which is organic, has been certified for maximum purity. More information is available at http://www.selenomax.com.
About Nutrition 21
Nutrition 21 is a nutritional bioscience company and the maker of chromium-based and omega-3 fish oil-based supplements with health benefits substantiated by clinical research. The company markets Chromax® chromium picolinate, http://www.chromax.com/, which is the most-studied form of the essential mineral chromium. Chromax, a supplement for healthy and pre-diabetic people that promotes insulin health and helps improve blood sugar metabolism, cardiovascular disease, control carbohydrate cravings and fight weight gain, is now available through food, drug and mass retailers nationwide. Nutrition 21 also developed and markets Diachrome®, http://www.diachrome.com/ , a proprietary, non-prescription, insulin sensitizer for people with type 2 diabetes. It is available in select drug retailers nationwide. Nutrition 21 holds 33 patents for nutrition products and uses, 23 of which are for chromium compounds and their uses. The Company is the exclusive importer of Icelandic fish oils, including omega-3 fatty acids, which are manufactured to pharmaceutical standards and sold under the Iceland Health® brand, http://www.icelandhealth.info. More information is available at http://www.nutrition21.com.
(1) Hurwitz, B. Suppression of Human Immunodeficiency Virus Type 1 Viral Load with Selenium Supplementation. Archives of Internal Medicine. Volume 167: January, 22 2007 (http://archinte.ama-assn.org).
(2) The Henry J. Kaiser Family Foundation. National Aids Treatment Information Project, 1998. http://www.kff.org/hivaids/1184-viral_load.cfm
(3) Clark, L.C. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. Journal of the American Medical Association. Volume 276: December 1996.
(4) Centers for Disease Control & Prevention (CDC). The Toll of the HIV Epidemic. Last reviewed April 19, 2006. http://www.cdc.gov/hiv/resources/reports/comp_hiv_prev/ epidemic_toll.htm (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
(5) UNAIDS, 2006 AIDS Epidemic Update, December 2006.
16.08.07 11:06
#454
TradingAsket
ChangeWave: One of our favorite microcaps
http://changewave.com/freecontent/...iance-FoodAsMedicine-081407.html
The rise of retail medicine signals big future for science-based nutrition
By Josh Levine
Food-as-medicine is a concept increasingly accepted -- and even embraced -- by consumers.
Due to advancements in medical science and a vast compilation of nutritional studies, the old saying "you are what you eat" is now virtually accepted as a universal truth.
Even though science-based nutrition -- including food-as-medicine -- is thought to hold great promise, growth has historically been lackluster due to a deficit of physician focus on smart nutritional habits and preventive medicine.
A recent ChangeWave Alliance survey on retail medicine indicated this may be changing, as bioactive foods, dietary supplements and nutritional counseling showed increased momentum within the healthcare industry.
I should add that these trends especially bode well for an exciting little company that we've recommended in our ChangeWave MicroCap Investor advisory service. But more of that later. Let's first look at key trends.
No one can predict the future, but at ChangeWave Investing we’ve got the next best thing -- the ChangeWave Alliance. Made up of 10,000 strategically positioned experts, the Alliance can let you in on opportunities and risks months ahead of the crowd! Click here to learn how.
Food for Thought
The business of retail medicine focuses on unique, personalized products and services that help patients manage their healthcare, but these products and services are paid for by the patients and not their insurance company. It's a robust business, according to the 279 healthcare industry respondents who participated in our most recent survey.
Seventy-six percent of our respondents who work in a medical practice, hospital or clinic said they see a trend toward retail medicine at their location. They cited nutrition and dietary products and programs as the biggest growth drivers.
Moreover, 24% reported that their medical work locales sold dietary products and services directly to their patients -- and another 14% said they plan to begin doing so in the next 12 months.
But what dietary products and services are sold currently at these practices, hospitals and clinics? And what ones will begin to be sold during the coming year?
Diet & Nutritional Products/Services Sold to Patients
Current and Future Market Share
Among those who sold dietary products and services at their practice, 70% said they sell nutritional counseling and services and 65% said they sell vitamins. Similarly, among those who said they plan to begin selling dietary products and services in the next 12 months, 55% said they will sell nutritional counseling and services, 50% said vitamins, and 50% said dietary supplements.
We noted that the strongest momentum is in bioactive foods, which increased from 14% currently to 26% of respondents who reported that their locale plans to begin selling them in the next 12 months.
Bioactive foods contain bio-molecules that modulate metabolism and treat specific conditions such as high blood glucose levels. Such foods are just beginning to come to market on a mass scale, and some analysts believe they may revolutionize how certain conditions are treated.
NXXI -- Healthy for Your Portfolio
Turning to one of our favorite microcaps -- New York-based Nutrition 21 (NXXI) is developing both dietary supplements and bioactive foods to treat specific conditions such as high blood glucose levels.
What makes Nutrition 21 stand apart from the crowd is that it's a true bioscience company -- not a run-of-the-mill reseller -- that approaches nutrition in a way similar to how pharmaceutical firms create their drugs:
* NXXI develops products based on a strong foundation of research and development and has an extensive patent portfolio that it has aggressively and successfully defended.
* The company performs numerous clinical studies with leading academic, institutional and government partners.
* NXXI proactively engages and educates the medical community about the advantages of its proprietary products.
As you can tell, I'm quite excited about the company. Importantly, Nutrition 21 relies on large-scale, double-blind, placebo-controlled, clinical trials as a key element to its marketing strategy.
This is critical to its future success, as healthcare providers are most likely to rely on FDA-approved drugs as the first choice of therapy for patients -- particularly those suffering from high-risk chronic diseases.
Today, Nutrition 21 is in the beginning stages of transforming from an ingredient supplier to a seller of branded, therapeutic products for a wide range of diseases including obesity, pre-diabetes, diabetes, cardiovascular health, and arthritis and joint health.
Its business strategy is already making an impact.
Revenues for the most recent quarter (fiscal Q3) soared more than 500% to $16.1 million, of which $13.6 million were from sales of innovative branded products like Diachrome for people with Type 2 diabetes.
Based on the above trends in retail medicine, and on sharply improving corporate fundamentals, Nutrition 21 looks well situated for a very profitable future.
The rise of retail medicine signals big future for science-based nutrition
By Josh Levine
Food-as-medicine is a concept increasingly accepted -- and even embraced -- by consumers.
Due to advancements in medical science and a vast compilation of nutritional studies, the old saying "you are what you eat" is now virtually accepted as a universal truth.
Even though science-based nutrition -- including food-as-medicine -- is thought to hold great promise, growth has historically been lackluster due to a deficit of physician focus on smart nutritional habits and preventive medicine.
A recent ChangeWave Alliance survey on retail medicine indicated this may be changing, as bioactive foods, dietary supplements and nutritional counseling showed increased momentum within the healthcare industry.
I should add that these trends especially bode well for an exciting little company that we've recommended in our ChangeWave MicroCap Investor advisory service. But more of that later. Let's first look at key trends.
No one can predict the future, but at ChangeWave Investing we’ve got the next best thing -- the ChangeWave Alliance. Made up of 10,000 strategically positioned experts, the Alliance can let you in on opportunities and risks months ahead of the crowd! Click here to learn how.
Food for Thought
The business of retail medicine focuses on unique, personalized products and services that help patients manage their healthcare, but these products and services are paid for by the patients and not their insurance company. It's a robust business, according to the 279 healthcare industry respondents who participated in our most recent survey.
Seventy-six percent of our respondents who work in a medical practice, hospital or clinic said they see a trend toward retail medicine at their location. They cited nutrition and dietary products and programs as the biggest growth drivers.
Moreover, 24% reported that their medical work locales sold dietary products and services directly to their patients -- and another 14% said they plan to begin doing so in the next 12 months.
But what dietary products and services are sold currently at these practices, hospitals and clinics? And what ones will begin to be sold during the coming year?
Diet & Nutritional Products/Services Sold to Patients
Current and Future Market Share
Among those who sold dietary products and services at their practice, 70% said they sell nutritional counseling and services and 65% said they sell vitamins. Similarly, among those who said they plan to begin selling dietary products and services in the next 12 months, 55% said they will sell nutritional counseling and services, 50% said vitamins, and 50% said dietary supplements.
We noted that the strongest momentum is in bioactive foods, which increased from 14% currently to 26% of respondents who reported that their locale plans to begin selling them in the next 12 months.
Bioactive foods contain bio-molecules that modulate metabolism and treat specific conditions such as high blood glucose levels. Such foods are just beginning to come to market on a mass scale, and some analysts believe they may revolutionize how certain conditions are treated.
NXXI -- Healthy for Your Portfolio
Turning to one of our favorite microcaps -- New York-based Nutrition 21 (NXXI) is developing both dietary supplements and bioactive foods to treat specific conditions such as high blood glucose levels.
What makes Nutrition 21 stand apart from the crowd is that it's a true bioscience company -- not a run-of-the-mill reseller -- that approaches nutrition in a way similar to how pharmaceutical firms create their drugs:
* NXXI develops products based on a strong foundation of research and development and has an extensive patent portfolio that it has aggressively and successfully defended.
* The company performs numerous clinical studies with leading academic, institutional and government partners.
* NXXI proactively engages and educates the medical community about the advantages of its proprietary products.
As you can tell, I'm quite excited about the company. Importantly, Nutrition 21 relies on large-scale, double-blind, placebo-controlled, clinical trials as a key element to its marketing strategy.
This is critical to its future success, as healthcare providers are most likely to rely on FDA-approved drugs as the first choice of therapy for patients -- particularly those suffering from high-risk chronic diseases.
Today, Nutrition 21 is in the beginning stages of transforming from an ingredient supplier to a seller of branded, therapeutic products for a wide range of diseases including obesity, pre-diabetes, diabetes, cardiovascular health, and arthritis and joint health.
Its business strategy is already making an impact.
Revenues for the most recent quarter (fiscal Q3) soared more than 500% to $16.1 million, of which $13.6 million were from sales of innovative branded products like Diachrome for people with Type 2 diabetes.
Based on the above trends in retail medicine, and on sharply improving corporate fundamentals, Nutrition 21 looks well situated for a very profitable future.
17.10.09 01:34
#456
butzerle
Muss den Uraltthread reanimieren / aktueller Grund
Die gute Nutrition hat nun Zahlen vorgelegt. einem leicht positiven EBITDA stehen enorme Abschreibungen gegenüber.
Zwar hat die Firma mit einem Kreditgeber eine Übereinkunft getroffen bis Mitte November, aber es sieht auch mit Cash sehr eng aus.
Heute massiv gefallen, fast auf ein ATL (das liegt bei 6c mittlerweile). Außerdem wird der Wert aus der Nasdaq geworfen, so wie es aussieht ist Montag letzer Handelstag.
Habe dennoch heute mal 10.000 eingekauft bei 8,5 cent.
Firma mit 6 Millionen Wert (also weniger als 1/6 des Jahresumsatzes) nun auch schon wie ein Chapter 11 Titel gehandelt. Wird wohl OTC weitergehen
Zwar hat die Firma mit einem Kreditgeber eine Übereinkunft getroffen bis Mitte November, aber es sieht auch mit Cash sehr eng aus.
Heute massiv gefallen, fast auf ein ATL (das liegt bei 6c mittlerweile). Außerdem wird der Wert aus der Nasdaq geworfen, so wie es aussieht ist Montag letzer Handelstag.
Habe dennoch heute mal 10.000 eingekauft bei 8,5 cent.
Firma mit 6 Millionen Wert (also weniger als 1/6 des Jahresumsatzes) nun auch schon wie ein Chapter 11 Titel gehandelt. Wird wohl OTC weitergehen